Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

What is Nucala for COPD? Nucala (mepolizumab) is an injectable therapy approved in the U.S. for adults with poorly controlled chronic obstructive pulmonary disease (COPD) who have high counts of ...

Nucala (mepolizumab) is a prescription drug used to treat a severe type of asthma and certain other inflammatory conditions. Nucala comes as an injection that you give under your skin. Nucala ...

Nearly 70% of patients in the US who are inadequately controlled on inhaled triple therapy have a BEC ≥150 cells/μL ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...

On May 18, at the 2025 American Thoracic Society (ATS) International Conference, updated findings from a post hoc analysis poster presentation of the Phase III MATINEE trial (NCT04133909) reinforced ...

Nucala, an anti–interleukin-5 (IL-5) monoclonal antibody developed by GSK, was associated with a sustained reduction in emergency department (ED) visits, hospitalisations, and symptom burden for ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as a supplementary treatment for elderly individuals with severe chronic obstructive pulmonary disease (COPD). Nucala is the ...

1. Why am I being given NUCALA? NUCALA contains the active ingredient mepolizumab. NUCALA is used to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...